Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology company focused on developing small molecule drugs for virology and immunology indications, has announced its upcoming participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference.
The management team will deliver their presentation on Thursday, March 27, 2025, at 11:00 a.m. ET. Interested parties can access the live webcast through the 'Events and Presentations' section on the 'Investors' page of Enanta's website. A replay will be available post-presentation and remain accessible for a minimum of 30 days.
Enanta Pharmaceuticals (NASDAQ:ENTA), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di farmaci a piccole molecole per indicazioni di virologia e immunologia, ha annunciato la sua prossima partecipazione alla 3ª Conferenza Virtuale Annuale sulle Malattie Autoimmuni e Infiammatorie di H.C. Wainwright.
Il team di gestione presenterà il proprio intervento giovedì 27 marzo 2025, alle 11:00 ET. Le parti interessate possono accedere alla diretta tramite la sezione 'Eventi e Presentazioni' nella pagina 'Investitori' del sito web di Enanta. Una registrazione sarà disponibile dopo la presentazione e rimarrà accessibile per un minimo di 30 giorni.
Enanta Pharmaceuticals (NASDAQ:ENTA), una compañía de biotecnología en etapa clínica centrada en el desarrollo de fármacos de pequeñas moléculas para indicaciones de virología e inmunología, ha anunciado su próxima participación en la 3ª Conferencia Virtual Anual sobre Enfermedades Autoinmunitarias e Inflamatorias de H.C. Wainwright.
El equipo directivo realizará su presentación el jueves 27 de marzo de 2025, a las 11:00 a.m. ET. Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección 'Eventos y Presentaciones' en la página 'Inversores' del sitio web de Enanta. Una repetición estará disponible después de la presentación y seguirá accesible durante un mínimo de 30 días.
Enanta Pharmaceuticals (NASDAQ:ENTA)는 바이러스학 및 면역학 적응증을 위한 소분자 약물 개발에 주력하는 임상 단계 생명공학 회사로, H.C. Wainwright 제3회 자가면역 및 염증 질환 가상 회의에 참여할 예정이라고 발표했습니다.
경영진은 2025년 3월 27일 목요일 오전 11시(ET)에 발표를 진행할 것입니다. 관심 있는 분들은 Enanta 웹사이트의 '투자자' 페이지에 있는 '이벤트 및 발표' 섹션을 통해 생중계에 접속할 수 있습니다. 발표 후에는 재생이 가능하며 최소 30일 동안 접근할 수 있습니다.
Enanta Pharmaceuticals (NASDAQ:ENTA), une entreprise de biotechnologie en phase clinique axée sur le développement de médicaments à petites molécules pour des indications en virologie et en immunologie, a annoncé sa prochaine participation à la 3ème Conférence Virtuelle Annuelle sur les Maladies Auto-immunes et Inflammatoires de H.C. Wainwright.
Le comité de direction présentera son intervention le jeudi 27 mars 2025, à 11h00 ET. Les parties intéressées peuvent accéder à la diffusion en direct via la section 'Événements et Présentations' de la page 'Investisseurs' du site web d'Enanta. Un enregistrement sera disponible après la présentation et restera accessible pendant au moins 30 jours.
Enanta Pharmaceuticals (NASDAQ:ENTA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von niedermolekularen Medikamenten für virologische und immunologische Indikationen konzentriert, hat seine bevorstehende Teilnahme an der 3. Virtuellen Jahreskonferenz zu Autoimmun- und Entzündungserkrankungen von H.C. Wainwright bekannt gegeben.
Das Managementteam wird seine Präsentation am Donnerstag, den 27. März 2025, um 11:00 Uhr ET halten. Interessierte Parteien können über den Bereich 'Veranstaltungen und Präsentationen' auf der 'Investoren'-Seite der Enanta-Website auf das Live-Webcast zugreifen. Eine Wiederholung wird nach der Präsentation verfügbar sein und mindestens 30 Tage lang zugänglich bleiben.
- None.
- None.
A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317551004/en/
Media and Investor Contact
Jennifer Viera
617-744-3848
jviera@enanta.com
Source: Enanta Pharmaceuticals, Inc.
FAQ
When is Enanta Pharmaceuticals (ENTA) presenting at the H.C. Wainwright Conference 2025?
How can investors watch Enanta Pharmaceuticals' (ENTA) presentation at the H.C. Wainwright Conference?
How long will the replay of ENTA's H.C. Wainwright Conference presentation be available?
What is the focus area of Enanta Pharmaceuticals' (ENTA) drug development?
